Arcutis Biotherapeutics, Inc.
ARQT US
ARQT USArcutis Biotherapeutics, Inc.
US5.83
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
- Business
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Company News
Arcutis Biotherapeutics Says Eczema Treatment Met Primary Endpoints
Arcutis Stock Rises on First TV Ad for Zoryve
Arcutis Biotherapeutics Finance Chief Scott Burrows to Exit
Arcutis Biotherapeutics: Chief Financial Officer Scott Burrows Is Leaving the Co to Pursue an External Opportunity >ARQT
Arcutis Biotherapeutics 2Q Loss/Shr $1.16 >ARQT
Arcutis Biotherapeutics Shares Rise 15% After CVS Caremark Covers Zoryve
Arcutis Biotherapeutics: Chief Comml Officer Ken Lock Stepping Down
Arcutis Biotherapeutics 1Q Loss/Shr $1.31 >ARQT
Arcutis Says Zoryve Has Received Regulatory Approval in Canada
Arcutis: FDA to Review Roflumilast Foam for Seborrheic Dermatitis
For Nvidia Shares, It’s Game On! Again
MDU Resources and AppHarvest See Activist Action
Mercury Systems and GMS See Activist Investor Action
Community West Bancshares, Funko See Activist Investor Action